Table 1. Baseline currents and percentage effects of PMA and SP
| Baseline I, μA | % effect of 30 nM PMA |
GIRK1/GIRK4 | 5.3 ± 1.4 | ─57.3 ± 4.3% (6) |
GIRK1-GIRK4Dimer | 4.3 ± 0.3 | ─54.6 ± 3.0% (5) |
GIRK1S185A/GIRK4S191A | 3.7 ± 0.4 | ─17.8 ± 2.0% (14) |
GIRK1S185D/GIRK4S191D | 1.7 ± 0.1 | 3.2 ± 1.4% (14) |
GIRK1F137S | 3.7 ± 0.5 | ─52.5 ± 7.8% (6) |
GIRK1F137S/S379A | 4.0 ± 1.5 | ─62.1 ± 3.3% (3) |
GIRK1F137S/S185A | 0.7 ± 0.0 | ─10.3 ± 4.7% (8) |
GIRK4S143T | 10.5 ± 5.7 | ─51.2 ± 3.6% (8) |
GIRK4S143T-T70A | 17.7 ± 7.2 | ─53.0 ± 7.4% (5) |
GIRK4S143T-S75A | 13.0 ± 2.2 | ─50.2 ± 4.7% (14) |
GIRK4S143T-S191A | 3.0 ± 0.3 | ─11.1 ± 4.8(16) |
GIRK4S143T-T199A | 3.5 ± 0.4 | ─45.2 ± 4.5% (7) |
GIRK4S143T-S209A | 14.6 ± 6.1 | ─50.8 ± 8.2% (5) |
GIRK4S143T-S227A | NF | NF |
GIRK4S143T-S241A | 3.1 ± 0.6 | ─48.8 ± 4.2% (7) |
GIRK4S143T-T244A | 7.8 ± 2.6 | ─44.0 ± 0.8% (11) |
GIRK4S143T-S320A | 13.7 ± 2.5 | ─43.6 ± 7.8% (14) |
GIRK4S143T-S321A | NF | NF |
GIRK4S143T-T338A | 5.9 ± 1.3 | ─53.7 ± 7.1% (11) |
GIRK4S143T-T350A | 7.0 ± 2.1 | -46.5 ± 8.1% (5) |
GIRK4S143T-I229A | 15.5 ± 1.8 | ─59.9 ± 3.7% (10) |
GIRK4S143T-I229A-S227A | NF | NF |
GIRK4S143T-I229A-S321A | 5.3 ± 1.0 | ─59.6 ± 3.9% (9) |
GIRK1-GIRK4/CPT-C | 3.0 ± 0.4 | ─0.9 ± 6.8% (9) |
GIRK1-GIRK4/CLT | 4.5 ± 1.0 | ─10.8 ± 5.2% (7) |
|
| % effect of 1 μM SP |
GIRK1-GIRK4 (control for SP) | 6.9 ± 1.5 | ─4.0 ± 3.2% (5) |
GIRK1-GIRK4+NK1R | 4.1 ± 0.6 | ─34.2 ± 1.9% (8) |
GIRK1S185A/GIRK4S191A+ NK1R | 1.9 ± 0.4 | 1.1 ± 2.3% (12) |
GIRK1S185D/GIRK4S191D+ NK1R | 2.9 ± 0.5 | 4.7 ± 0.8% (6) |
GIRK4*I229L+NK1R | 5.9 ± 0.9 | 20.3 ± 2.1% (4) |
GIRK1-GIRK4+NK1R/CPT-C | 3.1 ± 0.3 | 15.5 ± 11.0% (6) |
GIRK1-GIRK4+NK1R/CLT | 3.8 ± 0.8 | 12.4 ± 8.1% (5) |
CLT, chelerythine; CPT-C, calphostin-C; NF, nonfunctional; NK1R, substance P receptor; SP, substance P; PMA, phorbol 12-myristate 13-acetate. Data are shown as means ± SE, with number of cells shown in parentheses.